Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses

ByTeam Inspry September 26, 2023December 9, 2023

This review summarizes current information regarding coronavirus classification and characterization and presents the broad clinical consequences of SARS-CoV-2 activation of the angiotensin-converting enzyme 2 (ACE2) receptor expressed in different human cell types. It provides publicly available knowledge on the chemical nature of proposed therapeutics and their target biomolecules to assist in the identification of potentially new drugs for the treatment of SARS-CoV-2 infection. Photo Credit: Teslari Mihai

Featured | Immunology

What do we know about the function of SARS-CoV-2 proteins?

ByTeam Inspry September 19, 2023December 9, 2023

fter more than two years since the first report of COVID-19, it remains crucial to continue studying how SARS-CoV-2 proteins interact with the host metabolism to cause COVID-19. This review summarizes the findings regarding the functions of the 16 non-structural, 6 accessory and 4 structural SARS-CoV-2 proteins.

Featured | Variants

New COVID variant Pirola comes with unusual symptoms

ByTeam Inspry October 26, 2023December 2, 2023

The COVID variants Pirola (BA.2.86) as well as Eris (EG.5.1) are spreading faster and faster. Especially Pirola which seems to be even more easily transmissible than all other Corona mutations.

Featured | Surveillance

National governance and excess mortality due to COVID-19 in 213 countries: a retrospective analysis and perspectives on future pandemics

Bydlynne@latebloomercreative.com October 31, 2023December 9, 2023

National governance may have influenced the response of institutions to the Covid-19 pandemic, being a key factor in preparing for the next pandemics. The objective was to analyze the association between excess mortality due to COVID-19 (daily and cumulative per 100 thousand people) and national governance indicators in 213 countries.

Clinical Management

Antiviral combination therapies for persistent COVID-19 in immunocompromised patients

Bydlynne@latebloomercreative.com September 30, 2023December 9, 2023

After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls upon immunocompromised patients who cannot mount an endogenous immune response after both vaccination and/or natural infection. In this narrative review, the authors show that combinations of either small molecule antivirals or small molecule antiviral plus passive immunotherapies are safe and effective…

Clinical Management | Featured

Critical care and pandemic preparedness and response

Bydlynne@latebloomercreative.com November 13, 2023December 9, 2023

This review provides an introduction to an array of topics that pertain to different states of pandemic acuity: interpandemic preparedness, alert, surge activity, recovery and relapse through the literature and experience of recent pandemics including COVID-19, H1N1, Ebola, and SARS.

Featured | Vaccines

Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses

Bydlynne@latebloomercreative.com October 11, 2023February 11, 2024

Researchers are actively pursuing the development of next-generation and universal influenza vaccines to provide comprehensive protection against potential pandemic subtypes or strains. This review outlines the critical challenges and advancements in research and development (R&D) and highlights the improvements in regulatory responses for influenza vaccines.

Similar Posts

Contact